Investigators conducted a registry analysis including adult acute myeloid leukemia (AML) patients in remission who had received thiotepa, busulfan, and fludarabine or treosulfan-basedconditioning for haplo-hematopoietic stem cell transplant with posttransplant cyclophosphamide between 2010 and 2020.
[Hemasphere]